In studies of human tumour xenografts in mice we were able to demonstrate that decitabine treatment reduced the level of methylation of the hMLH1 gene promoter and that this was associated with re-expression of MLH1 in a small proportion of the tumour cells at doses that clearly conferred increased sensitisation and were well tolerated. Here, MLH1 is linked to neoplasm.